ClinicalTrials.gg
CompletedNCT00160615Updated Jun 10, 2019Results posted

Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method

A Phase 3 interventional study of Levetiracetam in Epilepsy, Partial, sponsored by UCB Japan Co. Ltd.. Completed. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2019-06-10.

Sponsored by UCB Japan Co. Ltd. (part of UCB S.A.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 11 months after the study started (first participant enrolled Sep 2001, registered Sep 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
154
Allocation
Non-randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing levetiracetam in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Levetiracetam · Epilepsies, Partial.

Enrollment
10th of 18
154 · median 173
Started
2001
the only one that year
Phase 3
10 of 18
none open now
Registered
5th of 18
by date
Lead sponsor
2 of 18
UCB Japan Co. Ltd.

Among the 18 studies testing levetiracetam in Epilepsies, Partial, this one is the 10th largest by enrollment, is the only one that started in 2001, is one of 10 in phase 3, and was the 5th registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

None of the 18 studies testing levetiracetam in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing levetiracetam in Epilepsies, Partial as a file.
02

Study summary

The safety and efficacy of L059 was evaluated in patients who completed "N165 Clinical Trial of L059". They received L059 at a daily dose from 1,000 mg to 3,000 mg in addition to their standard concomitant AEDs

03

Conditions studied

  • Epilepsy, Partial

Browse trials for

Keywords

  • Epilepsy, partial
  • Keppra
  • Levetiracetam
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who completed the evaluation period (Week 16) of N165 Clinical Trial of L059
  • Patients/the parent or guardian wish to continue treatment with L059 and to enter N165 Follow-up Study, and also the investigator admit the necessity of the repeated intake of the drug for the patients.

Exclusion criteria

Exclusion Criteria:

  • Patients who had not participate in N165 Clinical Trial of L059.
  • Patients who had participated in N165 Clinical Trial of L059 with no intention of entering the follow-up study taking the same medication.
  • Patients had not been in compliance with requirements of Protocol for N165 Clinical Trial of L059 in the course of the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    Levetiracetam

    Subjects received oral tablets of Levetiracetam. This study N01020 (NCT00160615) was designed as a single group assignment study and as follow-up study, open for patients from N165 (NCT00600509). The differentiation into placebo and Levetiracetam in the results reporting section is based on the treatment of the previously conducted study N165 (NCT00600509).

    Drug: Levetiracetam

Interventions

  • * Pharmaceutical form: Film-coating tablets * Concentration: 250 mg/ 500 mg * Route of administration: oral use

    Also known as: Keppra

06

What researchers measure

Primary outcomes

  1. Partial (Type I) Seizure Frequency Per Week by Analysis Visit

    Number of Partial (Type I) seizures over the treatment period standardized to 1 week period.

    Time frame: From Baseline up to 54 months

  2. Partial (Type IA) Seizure Frequency Per Week by Analysis Visit

    Number of Partial (Type IA) seizures over the treatment period standardized to 1 week period.

    Time frame: From Baseline up to 54 months

  3. Partial (Type IB) Seizure Frequency Per Week by Analysis Visit

    Number of Partial (Type IB) seizures over the treatment period standardized to 1 week period.

    Time frame: From Baseline up to 54 months

  4. Partial (Type IC) Seizure Frequency Per Week by Analysis Visit

    Number of Partial (Type IC) seizures over the treatment period standardized to 1 week period.

    Time frame: From Baseline up to 54 months

Secondary outcomes

  1. Percentage Change From Baseline of Partial Onset Seizure Frequency (Type I Overall) Per Week by Analysis Visit

    Percentage change from baseline of of Partial (Type I) seizure frequency over the treatment period standardized to 1 week period. Negative values indicate improvement from Baseline.

    Time frame: From Baseline up to 54 months

  2. Percentage Change From Baseline of Partial Onset Seizure Frequency (Subtype IA) Per Week by Analysis Visit

    Percentage change from baseline of of Partial (Type IA) seizure frequency over the treatment period standardized to 1 week period. Negative values indicate improvement from Baseline.

    Time frame: From Baseline up to 54 months

  3. Percentage Change From Baseline of Partial Onset Seizure Frequency (Subtype IB) Per Week by Analysis Visit

    Percentage change from baseline of of Partial (Type IB) seizure frequency over the treatment period standardized to 1 week period. Negative values indicate improvement from Baseline.

    Time frame: From Baseline up to 54 months

  4. Percentage Change From Baseline of Partial Onset Seizure Frequency (Subtype IC) Per Week by Analysis Visit

    Percentage change from baseline of of Partial (Type IC) seizure frequency over the treatment period standardized to 1 week period. Negative values indicate improvement from Baseline.

    Time frame: From Baseline up to 54 months

07

Results

Posted Jun 10, 2019

Participant flow

The study started to enroll patients in September 2001 and concluded in January 2007.

Participant flow — Overall Study
MilestoneN165 Randomized Treatment PBON165 Randomized Treatment LEV
Started50101
Completed3256
Not completed1845
Withdrew: Adverse event512
Withdrew: Withdrawal by subject02
Withdrew: Lack of efficacy1123
Withdrew: Patient decision12
Withdrew: Investigator decision11
Withdrew: Ae agents had to be discontinued (exam.)01
Withdrew: Switch to surgical treatment02
Withdrew: Non-compliance was suspected01
Withdrew: Poor compliance01

Outcome measures

PrimaryPartial (Type I) Seizure Frequency Per Week by Analysis Visit

Number of Partial (Type I) seizures over the treatment period standardized to 1 week period.

Time frame:
From Baseline up to 54 months
Reported as:
Median · Number of Seizures (Type I) per week
Partial (Type I) Seizure Frequency Per Week by Analysis Visit
Number of Seizures (Type I) per weekN165 Randomized Treatment PBON165 Randomized Treatment LEV
>= 1 day(d) - <= 3 months(m)1.68 (1.18 to 4.06)2.19 (0.99 to 5.41)
> 3 m - <= 6 m1.69 (1.00 to 2.75)2.00 (0.87 to 4.48)
> 6 m - <= 9 m1.58 (0.88 to 2.69)1.78 (0.68 to 4.94)
> 9 m - <= 12 m1.41 (0.95 to 3.25)1.60 (0.60 to 5.05)
> 12 m - <= 15 m1.58 (1.06 to 2.50)1.55 (0.80 to 4.67)
> 15 m - <= 18 m1.36 (1.03 to 2.32)1.69 (0.75 to 4.80)
> 18 m - <= 21 m1.35 (0.72 to 1.96)1.51 (0.62 to 4.49)
> 21 m - <= 24 m1.30 (0.75 to 1.98)1.36 (0.67 to 3.17)
> 24 m - <= 27 m1.25 (0.56 to 2.38)1.33 (0.82 to 2.80)
> 27 m - <= 30 m1.30 (0.66 to 2.46)1.28 (0.72 to 2.75)
> 30 m - <= 33 m1.21 (0.71 to 2.65)1.33 (0.77 to 2.83)
> 33 m - <= 36 m1.14 (0.68 to 2.69)1.30 (0.71 to 3.31)
> 36 m - <= 39 m1.20 (0.65 to 2.92)1.28 (0.75 to 3.32)
> 39 m - <= 42 m1.25 (0.50 to 2.91)1.32 (0.58 to 2.62)
> 42 m - <= 45 m1.17 (0.79 to 2.41)1.28 (0.60 to 2.49)
> 45 m - <= 48 m0.95 (0.54 to 2.05)1.09 (0.25 to 1.58)
> 48 m - <= 51 m0.90 (0.31 to 1.61)0.70 (0.14 to 1.42)
> 51 m - <= 54 m1.06 (0.08 to 2.17)0.78 (0.11 to 1.33)
> 54 m1.16 (0.27 to 1.65)0.09 (0.08 to 1.16)
PrimaryPartial (Type IA) Seizure Frequency Per Week by Analysis Visit

Number of Partial (Type IA) seizures over the treatment period standardized to 1 week period.

Time frame:
From Baseline up to 54 months
Reported as:
Median · Number of Seizures (Type IA) per week
Partial (Type IA) Seizure Frequency Per Week by Analysis Visit
Number of Seizures (Type IA) per weekN165 Randomized Treatment PBON165 Randomized Treatment LEV
>= 1 d - <= 3 m0.86 (0.07 to 1.73)0.68 (0.06 to 4.41)
> 3 m - <= 6 m0.32 (0.06 to 1.44)0.83 (0.06 to 3.31)
> 6 m - <= 9 m0.24 (0.00 to 1.33)0.63 (0.05 to 4.67)
> 9 m - <= 12 m0.26 (0.00 to 1.23)0.50 (0.00 to 3.47)
> 12 m - <= 15 m0.57 (0.09 to 1.35)0.22 (0.00 to 2.74)
> 15 m - <= 18 m0.27 (0.00 to 1.32)0.30 (0.00 to 2.81)
> 18 m - <= 21 m0.10 (0.00 to 1.38)0.42 (0.00 to 1.82)
> 21 m - <= 24 m0.17 (0.06 to 1.00)0.43 (0.05 to 1.60)
> 24 m - <= 27 m0.29 (0.00 to 1.10)0.25 (0.00 to 1.41)
> 27 m - <= 30 m0.44 (0.00 to 1.06)0.17 (0.00 to 1.41)
> 30 m - <= 33 m0.24 (0.00 to 0.98)0.25 (0.08 to 1.32)
> 33 m - <= 36 m0.17 (0.00 to 0.83)0.29 (0.05 to 1.63)
> 36 m - <= 39 m0.14 (0.00 to 0.40)0.13 (0.04 to 1.50)
> 39 m - <= 42 m0.17 (0.00 to 0.83)0.28 (0.04 to 1.29)
> 42 m - <= 45 m0.09 (0.00 to 1.13)0.44 (0.08 to 1.03)
> 45 m - <= 48 m0.20 (0.08 to 0.97)0.48 (0.09 to 1.38)
> 48 m - <= 51 m0.44 (0.00 to 1.42)0.18 (0.00 to 1.17)
> 51 m - <= 54 m0.62 (0.00 to 1.59)0.17 (0.10 to 0.63)
> 54 m0.87 (0.14 to 1.65)0.08 (0.00 to 0.84)
PrimaryPartial (Type IB) Seizure Frequency Per Week by Analysis Visit

Number of Partial (Type IB) seizures over the treatment period standardized to 1 week period.

Time frame:
From Baseline up to 54 months
Reported as:
Median · Number of Seizures (Type IB) per week
Partial (Type IB) Seizure Frequency Per Week by Analysis Visit
Number of Seizures (Type IB) per weekN165 Randomized Treatment PBON165 Randomized Treatment LEV
>= 1 d - <= 3 m1.56 (0.94 to 2.49)1.27 (0.50 to 3.25)
> 3 m - <= 6 m1.51 (0.81 to 2.69)1.13 (0.38 to 3.18)
> 6 m <= 9 m1.30 (0.60 to 2.25)0.92 (0.25 to 2.31)
> 9 m - <= 12 m1.39 (0.80 to 1.88)0.72 (0.24 to 2.11)
> 12 m - <= 15 m1.34 (0.71 to 1.94)0.81 (0.38 to 2.12)
> 15 m - <= 18 m1.25 (0.81 to 2.21)0.81 (0.35 to 1.88)
> 18 m - <= 21 m1.25 (0.72 to 1.95)0.58 (0.31 to 2.34)
> 21 m - <= 24 m1.26 (0.70 to 1.90)0.73 (0.26 to 2.65)
> 24 m - <= 27 m1.21 (0.56 to 2.50)0.85 (0.13 to 2.05)
> 27 m - <= 30 m1.21 (0.66 to 3.33)0.98 (0.15 to 1.74)
> 30 m - <= 33 m1.25 (0.69 to 2.84)0.79 (0.20 to 2.04)
> 33 m - <= 36 m1.15 (0.76 to 2.91)0.96 (0.14 to 2.13)
> 36 m - <= 39 m1.28 (0.80 to 3.43)1.04 (0.17 to 2.48)
> 39 m - <= 42 m1.40 (0.66 to 3.48)0.77 (0.13 to 1.71)
> 42 m - <= 45 m1.22 (0.76 to 2.79)0.89 (0.08 to 1.52)
> 45 m - <= 48 m0.87 (0.46 to 2.89)0.27 (0.00 to 1.36)
> 48 m - <= 51 m0.74 (0.33 to 2.46)0.22 (0.02 to 1.15)
> 51 m - <= 54 m0.80 (0.46 to 3.64)0.19 (0.00 to 1.25)
> 54 m0.72 (0.54 to 1.33)0.09 (0.00 to 0.17)
PrimaryPartial (Type IC) Seizure Frequency Per Week by Analysis Visit

Number of Partial (Type IC) seizures over the treatment period standardized to 1 week period.

Time frame:
From Baseline up to 54 months
Reported as:
Median · Number of Seizures (Type IC) per week
Partial (Type IC) Seizure Frequency Per Week by Analysis Visit
Number of Seizures (Type IC) per weekN165 Randomized Treatment PBON165 Randomized Treatment LEV
>= 1 d - <= 3 m0.00 (0.00 to 0.31)0.00 (0.00 to 0.19)
> 3 m - <= 6 m0.00 (0.00 to 0.13)0.00 (0.00 to 0.07)
> 6 m - <= 9 m0.05 (0.00 to 0.19)0.00 (0.00 to 0.13)
> 9 m - <= 12 m0.06 (0.00 to 0.17)0.00 (0.00 to 0.06)
> 12 m - <= 15 m0.06 (0.00 to 0.07)0.00 (0.00 to 0.03)
> 15 m - <= 18 m0.00 (0.00 to 0.13)0.00 (0.00 to 0.06)
> 18 m - <= 21 m0.00 (0.00 to 0.17)0.00 (0.00 to 0.00)
> 21 m - <= 24 m0.05 (0.00 to 0.14)0.00 (0.00 to 0.00)
> 24 m - <= 27 m0.02 (0.00 to 0.17)0.00 (0.00 to 0.00)
> 27 m - <= 30 m0.04 (0.00 to 0.13)0.00 (0.00 to 0.00)
> 30 m - <= 33 m0.09 (0.00 to 0.16)0.00 (0.00 to 0.00)
> 33 m - <= 36 m0.06 (0.00 to 0.13)0.00 (0.00 to 0.00)
> 36 m - <= 39 m0.04 (0.00 to 0.08)0.00 (0.00 to 0.00)
> 39 m - <= 42 m0.08 (0.00 to 0.08)0.00 (0.00 to 0.00)
> 42 m - <= 45 m0.04 (0.00 to 0.19)0.00 (0.00 to 0.02)
> 45 m - <= 48 m0.02 (0.00 to 0.04)0.00 (0.00 to 0.00)
> 48 m - <= 51 m0.00 (0.00 to 0.04)0.00 (0.00 to 0.00)
> 51 m - <= 54 m0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
> 54 m0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
SecondaryPercentage Change From Baseline of Partial Onset Seizure Frequency (Type I Overall) Per Week by Analysis Visit

Percentage change from baseline of of Partial (Type I) seizure frequency over the treatment period standardized to 1 week period. Negative values indicate improvement from Baseline.

Time frame:
From Baseline up to 54 months
Reported as:
Median · Percent change
Percentage Change From Baseline of Partial Onset Seizure Frequency (Type I Overall) Per Week by Analysis Visit
Percent changeN165 Randomized Treatment PBON165 Randomized Treatment LEV
>= 1 d - <= 3 m-27.39 (-48.11 to 5.37)-31.24 (-61.33 to 2.86)
> 3 m - <= 6 m-35.15 (-58.61 to -6.20)-34.74 (-62.48 to -3.22)
> 6 m - <= 9 m-38.42 (-59.44 to 5.08)-43.03 (-77.38 to -9.61)
> 9 m - <= 12 m-41.44 (-61.30 to -6.63)-43.11 (-73.76 to -11.60)
> 12 m - <= 15 m-29.58 (-58.69 to -10.04)-46.38 (-73.80 to -11.12)
> 15 m - <= 18 m-44.44 (-70.68 to -19.37)-43.17 (-69.33 to -16.84)
> 18 m - <= 21 m-37.58 (-69.96 to -21.23)-49.61 (-71.95 to -20.04)
> 21 m - <= 24 m-45.75 (-59.76 to -15.74)-52.96 (-77.16 to -13.78)
> 24 m - <= 27 m-50.89 (-69.36 to 0.01)-53.78 (-73.22 to -23.05)
> 27 m - <= 30 m-40.54 (-74.09 to -1.74)-47.71 (-76.29 to -18.07)
> 30 m - <= 33 m-29.96 (-69.05 to 0.00)-43.09 (-76.80 to -16.09)
> 33 m - <= 36 m-40.03 (-72.14 to -5.33)-39.01 (-75.01 to -11.31)
> 36 m - <= 39 m-43.67 (-68.70 to 3.89)-44.42 (-74.06 to -9.63)
> 39 m - <= 42 m-42.88 (-65.68 to 0.20)-47.69 (-85.88 to -10.34)
> 42 m - <= 45 m-45.06 (-57.76 to -21.01)-71.96 (-85.97 to -21.29)
> 45 m - <= 48 m-42.41 (-71.81 to -28.73)-80.02 (-86.42 to -36.37)
> 48 m - <= 51 m-49.11 (-74.26 to -23.92)-78.28 (-88.06 to -55.91)
> 51 m - <= 54 m-43.74 (-96.55 to 0.60)-81.81 (-92.97 to -66.12)
> 54 m-40.72 (-76.94 to -14.12)-90.00 (-92.17 to -85.37)
SecondaryPercentage Change From Baseline of Partial Onset Seizure Frequency (Subtype IA) Per Week by Analysis Visit

Percentage change from baseline of of Partial (Type IA) seizure frequency over the treatment period standardized to 1 week period. Negative values indicate improvement from Baseline.

Time frame:
From Baseline up to 54 months
Reported as:
Median · Percent change
Percentage Change From Baseline of Partial Onset Seizure Frequency (Subtype IA) Per Week by Analysis Visit
Percent changeN165 Randomized Treatment PBO (FAS)N165 Randomized Treatment LEV (FAS)
>= 1 d - <= 3 m-79.58 (-89.22 to -24.55)-45.93 (-88.28 to 14.97)
> 3 m - <= 6 m-77.15 (-95.81 to -43.42)-58.81 (-83.66 to 9.91)
> 6 m - <= 9 m-71.71 (-100.00 to -39.06)-61.62 (-86.96 to 45.98)
> 9 m - <= 12 m-66.05 (-100.00 to -42.98)-69.01 (-99.09 to -24.55)
> 12 m - <= 15 m-37.32 (-96.72 to -19.64)-78.44 (-100.00 to -43.42)
> 15 m - <= 18 m-79.55 (-100.00 to -46.11)-71.42 (-93.19 to -9.46)
> 18 m - <= 21 m-83.68 (-100.00 to -39.59)-66.07 (-97.31 to -19.52)
> 21 m - <= 24 m-82.30 (-99.71 to -50.87)-73.18 (-87.28 to -7.74)
> 24 m - <= 27 m-72.52 (-99.68 to -49.91)-74.85 (-91.27 to -33.43)
> 27 m - <= 30 m-74.89 (-98.71 to -46.15)-76.45 (-95.81 to -12.09)
> 30 m - <= 33 m-80.89 (-98.97 to -48.35)-78.24 (-89.74 to -4.31)
> 33 m - <= 36 m-84.13 (-100.00 to -48.15)-80.40 (-96.99 to 9.85)
> 36 m - <= 39 m-90.62 (-100.00 to -53.87)-76.79 (-97.71 to -27.78)
> 39 m - <= 42 m-92.50 (-100.00 to -42.88)-75.66 (-96.10 to -18.07)
> 42 m - <= 45 m-77.00 (-99.57 to -47.52)-74.09 (-93.06 to -39.64)
> 45 m - <= 48 m-71.43 (-91.25 to -47.31)-79.25 (-95.95 to -41.45)
> 48 m - <= 51 m-54.01 (-95.64 to -48.88)-91.41 (-100.00 to -56.26)
> 51 m - <= 54 m-64.18 (-100.00 to -42.73)-83.37 (-98.18 to -71.43)
> 54 m-59.19 (-92.21 to -32.87)-97.55 (-100.00 to -85.71)
SecondaryPercentage Change From Baseline of Partial Onset Seizure Frequency (Subtype IB) Per Week by Analysis Visit

Percentage change from baseline of of Partial (Type IB) seizure frequency over the treatment period standardized to 1 week period. Negative values indicate improvement from Baseline.

Time frame:
From Baseline up to 54 months
Reported as:
Median · Percent change
Percentage Change From Baseline of Partial Onset Seizure Frequency (Subtype IB) Per Week by Analysis Visit
Percent changeN165 Randomized Treatment PBO (FAS)N165 Randomized Treatment LEV (FAS)
>= 1 d - <= 3 m-21.41 (-48.68 to 19.61)-26.77 (-57.30 to 6.25)
> 3 m - <= 6 m-21.95 (-52.22 to 2.27)-31.35 (-64.47 to 0.53)
> 6 m - <= 9 m-28.30 (-52.22 to 7.30)-47.61 (-75.99 to -7.14)
> 9 m - <= 12 m-34.97 (-50.02 to 17.70)-43.56 (-73.35 to -14.31)
> 12 m - <= 15 m-21.12 (-54.73 to 7.78)-51.20 (-74.85 to 6.18)
> 15 m - <= 18 m-33.18 (-56.67 to 6.88)-45.80 (-66.80 to -12.59)
> 18 m - <= 21 m-32.78 (-54.73 to 2.63)-52.04 (-72.79 to -15.92)
> 21 m - <= 24 m-20.12 (-58.09 to 1.17)-52.96 (-78.82 to -10.93)
> 24 m - <= 27 m-28.75 (-61.84 to 13.15)-49.71 (-72.31 to -17.12)
> 27 m - <= 30 m-8.84 (-51.80 to 3.05)-48.18 (-79.29 to -21.93)
> 30 m - <= 33 m-15.85 (-52.14 to 16.16)-46.86 (-79.88 to -11.48)
> 33 m - <= 36 m-11.73 (-53.45 to 17.68)-42.03 (-74.93 to -6.07)
> 36 m - <= 39 m-15.06 (-49.40 to 28.76)-46.25 (-76.15 to 7.85)
> 39 m - <= 42 m-20.13 (-53.31 to 31.25)-49.85 (-86.73 to 0.00)
> 42 m - <= 45 m-23.76 (-46.47 to 13.76)-46.51 (-91.95 to -11.07)
> 45 m - <= 48 m-37.52 (-56.10 to -13.36)-54.05 (-98.11 to -16.56)
> 48 m - <= 51 m-42.17 (-53.57 to 1.70)-77.08 (-94.99 to -38.37)
> 51 m - <= 54 m5.38 (-44.75 to 10.33)-74.58 (-100.00 to 42.13)
> 54 m3.55 (-47.49 to 74.45)-86.61 (-93.85 to -8.06)
SecondaryPercentage Change From Baseline of Partial Onset Seizure Frequency (Subtype IC) Per Week by Analysis Visit

Percentage change from baseline of of Partial (Type IC) seizure frequency over the treatment period standardized to 1 week period. Negative values indicate improvement from Baseline.

Time frame:
From Baseline up to 54 months
Reported as:
Median · Percent change
Percentage Change From Baseline of Partial Onset Seizure Frequency (Subtype IC) Per Week by Analysis Visit
Percent changeN165 Randomized Treatment PBON165 Randomized Treatment LEV
>= 1 d - <= 3 m-100.00 (-100.00 to -24.55)-100.00 (-100.00 to -32.50)
> 3 m - <= 6 m-93.96 (-100.00 to -59.36)-100.00 (-100.00 to -32.10)
> 6 m - <= 9 m-88.73 (-100.00 to 38.32)-100.00 (-100.00 to -43.42)
> 9 m - <= 12 m-100.00 (-100.00 to -54.73)-100.00 (-100.00 to -40.03)
> 12 m - <= 15 m-88.33 (-100.00 to -49.70)-100.00 (-100.00 to -64.50)
> 15 m - <= 18 m-100.00 (-100.00 to -62.28)-100.00 (-100.00 to -69.82)
> 18 m - <= 21 m-90.42 (-100.00 to -54.73)-100.00 (-100.00 to -25.61)
> 21 m - <= 24 m-80.56 (-100.00 to -24.55)-100.00 (-100.00 to -68.35)
> 24 m - <= 27 m-91.92 (-100.00 to -24.55)-100.00 (-100.00 to -45.54)
> 27 m - <= 30 m-92.11 (-100.00 to -74.85)-100.00 (-100.00 to -45.54)
> 30 m - <= 33 m-77.02 (-95.91 to 16.78)-100.00 (-100.00 to -86.64)
> 33 m - <= 36 m-74.30 (-91.72 to -46.59)-100.00 (-100.00 to -92.19)
> 36 m - <= 39 m-85.67 (-96.25 to -7.06)-100.00 (-100.00 to -83.77)
> 39 m - <= 42 m-83.23 (-100.00 to -21.27)-100.00 (-100.00 to -47.52)
> 42 m - <= 45 m-79.75 (-100.00 to -56.26)-100.00 (-100.00 to -49.70)
> 45 m - <= 48 m-95.81 (-100.00 to -83.23)-100.00 (-100.00 to -85.94)
> 48 m - <= 51 m-95.98 (-100.00 to -87.62)-100.00 (-100.00 to -100.00)
> 51 m - <= 54 m-100.00 (-100.00 to -91.67)-100.00 (-100.00 to -100.00)
> 54 m-100.00 (-100.00 to -100.00)-100.00 (-100.00 to -100.00)

Adverse events

Collected over Adverse events were collected from Visit 1 (Week 0) until 2 weeks after termination (up to 54 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
N165 Randomized Treatment PBO (FAS)0/50 (0%)12/50 (24%)48/50 (96%)
N165 Randomized Treatment LEV (FAS)1/101 (1%)22/101 (21.8%)99/101 (98%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventN165 Randomized Treatment PBO (FAS)N165 Randomized Treatment LEV (FAS)
ConvulsionNervous system disorders1/505/101
Status epilepticusNervous system disorders2/504/101
PneumoniaInfections and infestations0/503/101
Abdominal pain lowerGastrointestinal disorders1/500/101
Difficulty in walkingGeneral disorders1/500/101
Gallbladder polypHepatobiliary disorders1/500/101
AppendicitisInfections and infestations1/500/101
ContusionInjury, poisoning and procedural complications1/500/101
FallInjury, poisoning and procedural complications1/501/101
Femoral neck fractureInjury, poisoning and procedural complications1/500/101
Most frequent other events
Showing 10 of 65
Most frequent other events
EventN165 Randomized Treatment PBO (FAS)N165 Randomized Treatment LEV (FAS)
NasopharyngitisInfections and infestations38/5076/101
ConvulsionNervous system disorders2/59/101
ContusionInjury, poisoning and procedural complications16/5029/101
HeadacheNervous system disorders16/5028/101
DiarrhoeaGastrointestinal disorders5/5027/101
SomnolenceNervous system disorders13/5025/101
DizzinessNervous system disorders12/5020/101
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders12/5022/101
ConstipationGastrointestinal disorders4/5020/101
PyrexiaGeneral disorders9/5014/101

Baseline characteristics

Full analysis Set (FAS)

Age, Continuous
Age, Continuous(Years)N165 Randomized Treatment PBO (FAS)N165 Randomized Treatment LEV (FAS)Total Title
Mean33.19 ± 9.9931.95 ± 10.1932.36 ± 10.11
Age, Customized
Age, Customized(Participants)N165 Randomized Treatment PBO (FAS)N165 Randomized Treatment LEV (FAS)Total Title
<=18 years268
Between 18 and 65 years4895143
Sex: Female, Male
Sex: Female, Male(Participants)N165 Randomized Treatment PBO (FAS)N165 Randomized Treatment LEV (FAS)Total Title
Female274774
Male235477
08

Study locations

No study locations are listed for this record.

09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2001 to primary completion in Jan 2007, 64 months.

Results were first posted in Jun 2019, 12 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2005
First posted
Sep 12, 2005
StartActual
Sep 12, 2001
Primary completionActual
Jan 17, 2007
CompletionActual
Jan 17, 2007
Results first posted
Jun 10, 2019
Last update
Jun 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00160615
Lead sponsor
UCB Japan Co. Ltd.
Responsible party
Sponsor
First posted
Sep 12, 2005
Start date
Sep 12, 2001
Primary completion
Jan 17, 2007
Completion
Jan 17, 2007
Results posted
Jun 10, 2019
Last update
Jun 10, 2019

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion